Acurx Pharmaceuticals Inc... (ACXP)
undefined
undefined%
At close: undefined
0.86
1.08%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.

The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.

Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc. logo
Country United States
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO David P. Luci CPA, Esq., J.D.

Contact Details

Address:
259 Liberty Avenue
Staten Island, New York
United States
Website https://www.acurxpharma.com

Stock Details

Ticker Symbol ACXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001736243
CUSIP Number 00510M104
ISIN Number US00510M1045
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
David P. Luci CPA, Esq., J.D. Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director
Robert G. Shawah CPA, CPA Co-Founder & Chief Financial Officer
Robert J. DeLuccia Co-Founder & Executive Chairman

Latest SEC Filings

Date Type Title
Nov 13, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Aug 09, 2024 8-K Current Report
Aug 08, 2024 10-Q Quarterly Report
Jun 18, 2024 4 Filing
Jun 18, 2024 4 Filing
Jun 18, 2024 4 Filing
Jun 18, 2024 4 Filing
Jun 18, 2024 4 Filing
Jun 17, 2024 8-K Current Report